Transdermal menopausal hormone therapy: delivery through skin changes the rules

Bibliography

• Chetkowski RJ, Meldrum DR, Steingold KA, Biologic effects of transdermal estradiol. N Engl J Med 1986;314(25):1615-20
   PubMed Web of Science ®Google Scholar
• Buckler HM, Robertson WR, Wu FC. Which androgen replacement therapy for women? J Clin Endocrinol Metab 1998;83(11):3920-4
   PubMed Web of Science ®Google Scholar
• O'Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol 1995;35(9 Suppl):18S-24S
   PubMed Web of Science ®Google Scholar
• Shifren JL. Androgens, estrogens, and metabolic syndrome at midlife. Menopause 2009;16(2):226-8
   PubMed Web of Science ®Google Scholar
• Shifren JL, Desindes S, Mcllwain M, A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women. Menopause 2007;14(6):985-94
   PubMed Web of Science ®Google Scholar
• Shifren JL, Rifai N, Desindes S, A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reative protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. J Clin endocrinol Metab 2008;93(5):1702-10
   PubMed Web of Science ®Google Scholar
• Bachmann GA. Menopausal vasomotor symptoms: a review of causes, effects and evidence-based treatment options. J Reprod Med 2005;50(3):155-65
   PubMed Web of Science ®Google Scholar
• Rapkin AJ. Vasomotor symptoms in menopause: physiologic conditions and central nervous system approaches to treatment. Am J Obstet Gynecol 2007;196(2):97-106
   PubMed Web of Science ®Google Scholar
• Dennerstein L, Koochaki P, Barton I, Graziottin A. Hypoactive sexual desire disorder in menopausal women: a survey of Western European women. J Sex Med 2006;3(2):212-22
   PubMed Web of Science ®Google Scholar
• Tataryn IV, Lomax P, Meldrum DR, Objective techniques for the assessment of postmenopausal hot flashes. Obstet Gynecol 1981;57(3):340-4
   PubMed Web of Science ®Google Scholar
• Sturdee DW. The menopausal hot flush—anything new? Maturitas 2008;60(3-4):257
   PubMedGoogle Scholar
• Andrikoula M, Prelevic G. Menopausal hot flushes revisited. Climacteric 2009;12(1):3-15
   PubMed Web of Science ®Google Scholar
• Buster JE. Low-dose estradiol spray: a novel treatment for vasomotor instability in postmenopausal women. Womens Health (Lond Engl) 2009;5(1):23-8
   PubMedGoogle Scholar
• Chlebowski RT, Hendrix SL, Langer RD, Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289(24):3243-53
   PubMed Web of Science ®Google Scholar
• Wassertheil-Smoller S, Hendrix SL, Limacher M, Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289(20):2673-84
   PubMed Web of Science ®Google Scholar
• Seifert-Klauss V, Kingwell E, Hitchcock CL, Estrogen and progestogen use in peri-and postmenopausal women. March 2007 position statement of The North American Menopause Society. Menopause 2007;14(2):168-82
   PubMed Web of Science ®Google Scholar
• Dennerstein L, Randolph J, Taffe J, Hormones, mood, sexuality, and the menopausal transition. Fertil Steril 2002;77(Suppl 4):S42-8
   PubMed Web of Science ®Google Scholar
• Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984;59(3):551-5
   PubMed Web of Science ®Google Scholar
• Rotter JI, Wong FL, Lifrak ET, Parker LN. A genetic component to the variation of dehydroepiandrosterone sulfate. Metabolism 1985;34(8):731-6
   PubMed Web of Science ®Google Scholar
• Crawford S, Santoro N, Laughlin GA, Circulating dehydroepiandrosterone sulfate concentrations during the menopausal transition. J Clin Endocrinol Metab 2009;94(8):2945-51
   Google Scholar
• Labrie F, Belanger A, Cusan L, Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 1997;82(8):2396-402
   PubMed Web of Science ®Google Scholar
• Basson R. Female sexual dysfunction in hypopituitarism. Lancet 2007;370(9589):737, 738
   PubMed Web of Science ®Google Scholar
• Judd HL, Lucas WE, Yen SS. Effect of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. Am J Obstet Gynecol 1974;118(6):793-8
   PubMed Web of Science ®Google Scholar
• Nathorst-Böös J, von Schoultz B, Carlström K. Effective ovarian removal and estrogen replacement therapy-effects on sexual life, physchological well-being and androgen status. J Psychosom Obstet Gynaecol 1993;14(4):283-93
   PubMedGoogle Scholar
• van der Stege JG, Groen H, van Zadelhoff SJ. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause 2008;15(1):23-31
   PubMed Web of Science ®Google Scholar
• Shifren JL, Braunstein GD, Simon JA, Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343(10):682-8
   Google Scholar
• Buster JE, Kingsberg SA, Aguirre O, Testosterone patch for low sexual desire in surgically menopausal women: a randomized tiral. Obstet Gynecol 2005;105(5Ptl):944-52
   PubMedGoogle Scholar
• Simon J, Braunstein G, Nachtigall L, Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90(9):5226-33
   PubMed Web of Science ®Google Scholar
• Braunstein GD, Sundwall DA, Katz M, Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 2005:165(14):1571-2
   PubMedGoogle Scholar
• Davis SR, van der Mooren MJ, Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause 2006;(3):387-96
   Google Scholar
• Shifren JL, Davis SR, Moreau M, Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause 2006:13(5):770-9
   PubMed Web of Science ®Google Scholar
• Davis SR, Moreau M, Kroll R, Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008;359(19):2005-17
   PubMed Web of Science ®Google Scholar
• A randomized study to compare the effectiveness, tolerability, and acceptability of two different transdermal estradiol replacement therapies. The Transdermal HRT Investigators Group. Int J Fertil Menopausal Stud 1993;38(1):5-11
   PubMedGoogle Scholar
• Reginster JY, Donazzolo Y, Brion N, Lins R. Estradiol pharmacokinetics after transdermal application of patches to postmenopausal women: matrix versus reservoir patches. Climacteric 2000;3(3):168-75
   PubMedGoogle Scholar
• Gordon SF. Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy. Am J Obstet Gynecol 1995;173(3 Pt2):998-1004
   PubMed Web of Science ®Google Scholar
• Simon Ja, Bouchard C, Waldbaum A, Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. Obstet Gynecol 2007;109(3):588-96
   PubMed Web of Science ®Google Scholar
• Buster JE, Koltun WD, Pascual ML, Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111(6):1343-51
   PubMed Web of Science ®Google Scholar
• Tikkanen MJ. The menopause and hormone replacement therapy: lipids, lipoproteins, coagulation and fibrinolytic factors. Maturitas 1996;23(2):209-16
   PubMed Web of Science ®Google Scholar
• Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001;75(5):898-915
   Google Scholar
• Georgiadou P, Sbarouni E. Effect of hormone replacement therapy on inflammatory biomarkers. Adv Clin Chem 2009;47:59-93
   PubMed Web of Science ®Google Scholar
• Zanger D, Yang BK, Ardans J, Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol 2000;36(6):1797-802
   PubMed Web of Science ®Google Scholar
• Chu MC, Cosper P, Nakhuda GS, Lobo RA. A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome. Fertil Steril 2006;86(6):1669-75
   PubMed Web of Science ®Google Scholar
• Norman RJ, Flight IH, Rees MC. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. Cochrane Datatabase Syst Rev. 2000;(2)CD001018
   Google Scholar
• Di Carlo C, Tommaselli GA, Sammartino A, Serum leptin levels and body composition in postmenopausal women: effects of hormone therapy. Menopause 2004;11(4):466-73
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288(3):321-33
   PubMed Web of Science ®Google Scholar
• Lokkegaard E, Andreasen AH, Jacobsen RK, Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J 2008;29(21):2660-8
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007:115(7):840-5
   PubMed Web of Science ®Google Scholar
• Straczek C, Oger E, Yon de Jonage-Canonico MB, Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation. 2005;112(22):3495-500
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Conrad, Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost 2006;4(6):1259-65
   PubMed Web of Science ®Google Scholar
• Abraham GE. Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle. J Clin Endocrinol Metab 1974;39(2):340-6
   PubMed Web of Science ®Google Scholar
• Labrie F, Luu-The V, Bélanger A, Is dehydroepiandrosterone a hormone? J Endocrinol 2005;187(2):169-96
   PubMed Web of Science ®Google Scholar
• Seibel M. Men, women and testosterone: why did the FDA fail Intrinsa? Sex Reprod Menopause 2005;(1):1-2
   Google Scholar
• Kronawitter D, Gooren L, Zoliver H, Effects of transdermal testosterone or oral dydrogesterone on hypoactive sexual desire disorder in transsexual women: results of a pilot study. Eur J Endocrinol 2009. [Epub ahead of print]
   Google Scholar
• Nathorst-Böös J, Flöter A, Jarkander-Rolff M, Treatment with percutanous testosterone gel in postmenopausal women with decreased libido-effects on sexuality and phychological general well-being. Maturitas 2006;53(1):11-8
   PubMed Web of Science ®Google Scholar
• Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on post menopausal bone density and sexuality. Maturitas 2008;61(1-2):17-26
   PubMed Web of Science ®Google Scholar
• Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995:21(3):227-36
   PubMed Web of Science ®Google Scholar
• Sherwin BB, Gelfand MM, Brender W. Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom Med 1985;47(4):339-51
   PubMed Web of Science ®Google Scholar
• Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 1987;49(4):397-409
   PubMed Web of Science ®Google Scholar
• Wierman ME, Basson R, Davis Sr, Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 2006;91(10):3697-710
   PubMed Web of Science ®Google Scholar
• North American Menopause Society. The role of testosterone therapy in postmenopausal women: position statement of The North American Menopaus Society. Menopause 2005;13(5):496-511
   Google Scholar
• Shufelt CL, Braunstein GD. Safety of testosterone use in women. Maturitas 2009;63(1):63-6
   PubMed Web of Science ®Google Scholar
• Shufelt CL, Braunstein GD. Testosterone and the breast. Menopause Int 2008;14(3):117-22
   PubMedGoogle Scholar
• Traish A, Guay AT, Spark RF. Testosterone Therapy in Women Study Group. Are the Encocrine Society's clinical practice guidelines on androgen therapy in women misguided? A commentary. J Sex Med 2007;4(5):1223-34, discussion 1234-5
   PubMed Web of Science ®Google Scholar
• Hubayter Z, Simon JA. Testosterone therapy for sexual dysfunction in post menopausal women. Climacteric 2008;11(3):181-91
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Simon JA, Goldstein I. The current outlook for testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. J Sex Med 2008;5(Suppl 4):182-93
   PubMedGoogle Scholar
• Braunstein GD. The Endocrine Society Clinical Practice Guideline and The North American Menopause Society position statement on androgen therapy in women: another one of Yogi's forks. J Clin Endocrinol Metab 2007;92(11):4091-3
   PubMed Web of Science ®Google Scholar
• van Staa TP, Sprafka JM. Study of adverse outcomes in women using testosterone therapy. Maturitas 2009;62(1):76-80
   PubMed Web of Science ®Google Scholar